Federal Register / Vol. 61, No. 99 / Tuesday, May 21, 1996 / Notices 25495

1Copies of the Consent Order and Set Aside

Order are available from the Commission’s Public

Reference Branch, H–130, 6th Street and

Pennsylvania Avenue NW., Washington, D.C.

20580.

SUPPLEMENTARY INFORMATION: On

Wednesday, November 8, 1995, there

was published in the Federal Register,

60 FR 56338, a proposed consent

agreement with analysis In the Matter of

The Stop & Shop Companies, Inc., et al.,

for the purpose of soliciting public

comment. Interested parties were given

sixty (60) days in which to submit

comments, suggestions or objections

regarding the proposed form of the

order.

No comments having been received,

the Commission has ordered the

issuance of the complaint in the form

contemplated by the agreement, made

its jurisdictional findings and entered

an order to divest, as set forth in the

proposed consent agreement, in

disposition of this proceeding.

(Sec. 6, 38 Stat. 721; 15 U.S.C. 46. Interprets

or applies sec. 5, 38 Stat. 719, as amended;

15 U.S.C. 45)

Donald S. Clark,

Secretary.

[FR Doc. 96–12706 Filed 5–20–96; 8:45 am]

BILLING CODE 6750–01–M

[Dkt. C–3244]

West Point-Pepperell, Inc.; Prohibited

Trade Practices and Affirmative

Corrective Actions

AGENCY: Federal Trade Commission.

ACTION: Set aside order.

SUMMARY: This order reopens a 1988

consent order—which required West

Point to divest certain towel and sheet

manufacturing facilities and prohibited

West Point, for 10 years, from making

certain acquisitions in the sheet and

towel industries without prior

Commission approval—and sets aside

the consent order pursuant to the

Commission’s Prior Approval Policy

Statement, under which the

Commission presumes that the public

interest requires setting aside the prior

approval requirements in outstanding

merger orders and making them

consistent with that policy.

DATES: Consent order issued December

14, 1988. Set aside order issued October

4, 1995.1

FOR FURTHER INFORMATION CONTACT:

Daniel Ducore, FTC/S–2115,

Washington, D.C. 20580, (202) 326–

2526.

SUPPLEMENTARY INFORMATION: In the

Matter of West Point-Pepperell, Inc. The

prohibited trade practices and/or

corrective actions are removed as

indicated.

Authority: Sec. 6, 38 Stat. 721; 15 U.S.C. 46.

Interpret or apply sec. 5, 38 Stat. 719, as

amended; sec. 7, 38 Stat. 731, as amended;

15 U.S.C. 45, 18)

Donald S. Clark,

Secretary.

[FR Doc. 96–12707 Filed 5–20–96; 8:45 am]

BILLING CODE 6750–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Centers for Disease Control and

Prevention

Citizens Advisory Committee on Public

Health Service Activities and Research

at Department of Energy (DOE) Sites:

Idaho National Engineering Laboratory

Health Effects Subcommittee

In accordance with section 10(a)(2) of

the Federal Advisory Committee Act

(Pub. L. 92–463), the Centers for Disease

Control and Prevention (CDC) announce

the following meeting.

Name: Citizens Advisory Committee

on Public Health Service Activities and

Research at Department of Energy (DOE)

Sites: Idaho National Engineering

Laboratory Health Effects Subcommittee

(INEL).

Times and Dates: 8 a.m.–5 p.m., June

5, 1996; 7 p.m.–9 p.m., June 5, 1996; 8

a.m.–12:15 p.m., June 6, 1996.

Place: Quality Inn Pocatello Park

Hotel, 1555, Pocatello Creek Road,

Pocatello, Idaho 83201.

Status: Open to the public, limited

only by the space available. The meeting

room accommodates approximately 50

people.

Purpose: The Subcommittee is

charged with providing advice and

recommendations to the Director, CDC,

and the Administrator, ATSDR,

regarding community, American Indian

Tribes, and labor concerns pertaining to

CDC’s and ATSDR’s public health

activities and research at respective

DOE sites. Activities shall focus on

providing a forum for community,

American Indian Tribal, and labor

interaction and serve as a vehicle for

community concern to be expressed as

advice and recommendations to CDC

and ATSDR.

Matters To Be Discussed: Agenda

items include: the Biological Effects of

Radiation—Radionuclides releases other

than plutonium that could cause health

effects, declassification issues, high

efficiency particulate air filters,

environmental monitoring—past and

present, discussion of Phase I, and other

than radionuclides present at INEL (e.g.,

chemicals: most toxic and carcinogenic).

Agenda items are subject to change as

priorities dictate.

Contact Persons For More

Information: Arthur J. Robinson or

Nadine Dickerson, Radiation Studies

Branch, Division of Environmental

Hazards and Health Effects, NCEH, CDC,

4770 Buford Highway, NE, M/S F–35,

Atlanta, Georgia 30341–3724, telephone

770/488–7040, FAX 770/488–7044.

Dated: May 15, 1996.

John C. Burckhardt,

Acting Director, Management Analysis and

Services Office, Centers for Disease Control

and Prevention (CDC).

[FR Doc. 96–12686 Filed 5–20–96; 8:45 am]

BILLING CODE 4163–18–M

Food and Drug Administration

[Docket No. 92N–0438]

Worldwide Biologicals, Inc.;

Revocation of U.S. License No. 832–

003

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

SUMMARY: The Food and Drug

Administration (FDA) is announcing the

revocation of the establishment license

(U.S. License No. 832–003) and the

product license issued to Worldwide

Biologicals, Inc., for the manufacture of

Source Plasma. A notice of opportunity

for a hearing on a proposal to revoke the

licenses was published in the Federal

Register of March 22, 1993. Worldwide

Biologicals, Inc., subsequently requested

a hearing. In a separate legal proceeding,

the responsible head of Worldwide

Biologicals, Inc., voluntarily

surrendered U.S. License No. 832–003

pursuant to a plea agreement with the

United States Attorney for the Southern

District of Ohio and the Office of

Consumer Litigation, United States

Department of Justice, which

represented FDA in the proceeding. In

light of Worldwide Biologicals, Inc.’s,

surrender of its license, the firm’s

request for an opportunity for a hearing

on the issue of license revocation

became moot. FDA, therefore,

proceeded to revoke the licenses.

DATES: The revocation of the

establishment license (U.S. License No.

832–003) and product license became

effective September 29, 1994.

FOR FURTHER INFORMATION CONTACT:

Stephen M. Ripley or Tracey H. Forfa,

Center for Biologics Evaluation and

Research (HFM–635), Food and Drug

Administration, 1401 Rockville Pike,